<p>The parameters are varied 25% in both ways (dark bars: 25% increase, light bars: 25% decrease). GP: general practitioner, ICER: incremental cost-effectiveness ratio, RSV: respiratory syncytial virus.</p
Introduction: Respiratory syncytial virus (RSV) infection is one of the major causes of respiratory ...
<p>Adjusted influenza vaccine effectiveness (IVE) assessed for all ages, <65 and> = 65, and by: a) v...
Background: RSV infects the majority of infants under one year, and is a leading cause of bronchioli...
<p><b>A</b>: the median impact of vaccination in terms of proportion of RSV hospital admissions aver...
<p>Key parameters varied in sensitivity analyses are shown on the left. Values in parentheses indica...
Vaccination cohorts 1–4 reached ≥14 days after vaccination with a Pfizer-BioNTech primary series dur...
<p>Incremental cost effectiveness ratio (ICER) for vaccination in children age 1–10, probability of ...
AbstractBackgroundDuring the period of this study, the American Academy of Pediatrics (AAP) 2006 gui...
<p>Sensitivity analysis of the vaccination coverage at the steady state of individuals decision maki...
<p>Age distribution was calculated as a function of duration of sterile and clinical immunity and <i...
<p>Sensitivity analysis of the parameters representing the rate of children maturing into adulthood ...
The objective of the paper is to assess the cost-effectiveness of targeted respiratory syncytial vir...
<p>Univariate sensitivity analysis for <i>E</i><sub><i>V</i></sub> and <i>E</i><sub><i>I</i></sub>. ...
Background Vaccines and prophylactic antibodies against respiratory syncytial virus (RSV) are in dev...
BACKGROUND: Vaccines and prophylactic antibodies against respiratory syncytial virus (RSV) are in de...
Introduction: Respiratory syncytial virus (RSV) infection is one of the major causes of respiratory ...
<p>Adjusted influenza vaccine effectiveness (IVE) assessed for all ages, <65 and> = 65, and by: a) v...
Background: RSV infects the majority of infants under one year, and is a leading cause of bronchioli...
<p><b>A</b>: the median impact of vaccination in terms of proportion of RSV hospital admissions aver...
<p>Key parameters varied in sensitivity analyses are shown on the left. Values in parentheses indica...
Vaccination cohorts 1–4 reached ≥14 days after vaccination with a Pfizer-BioNTech primary series dur...
<p>Incremental cost effectiveness ratio (ICER) for vaccination in children age 1–10, probability of ...
AbstractBackgroundDuring the period of this study, the American Academy of Pediatrics (AAP) 2006 gui...
<p>Sensitivity analysis of the vaccination coverage at the steady state of individuals decision maki...
<p>Age distribution was calculated as a function of duration of sterile and clinical immunity and <i...
<p>Sensitivity analysis of the parameters representing the rate of children maturing into adulthood ...
The objective of the paper is to assess the cost-effectiveness of targeted respiratory syncytial vir...
<p>Univariate sensitivity analysis for <i>E</i><sub><i>V</i></sub> and <i>E</i><sub><i>I</i></sub>. ...
Background Vaccines and prophylactic antibodies against respiratory syncytial virus (RSV) are in dev...
BACKGROUND: Vaccines and prophylactic antibodies against respiratory syncytial virus (RSV) are in de...
Introduction: Respiratory syncytial virus (RSV) infection is one of the major causes of respiratory ...
<p>Adjusted influenza vaccine effectiveness (IVE) assessed for all ages, <65 and> = 65, and by: a) v...
Background: RSV infects the majority of infants under one year, and is a leading cause of bronchioli...